Qwo

What is Qwo?

Have you been struggling with stubborn cellulite on your buttocks? You're not the only one–it's thought that nine in ten women will experience cellulite at some point in their lives. Cellulite dimples are not caused by fat, but rather result from the thickening of fibrous bands under the skin, making them frustratingly impervious to changes in diet, and exercise. Qwo, the first and only injectable approved by the FDA for treatment of moderate to severe cellulite in the buttocks of adult women, can help.

Qwo contains collagenases, a class of enzymes that target the fibrous bands under the skin. Though the exact mechanism of action by which Qwo works is not fully known, it is thought that these enzymes help release the tension caused by these bands, stimulate the growth of new collagen, and aid in fat redistribution.

 

What can I Expect from Treatment?

Qwo has been found to be effective in reducing the appearance of moderate to severe cellulite in the buttocks of adult women. A course of treatment involves three injection appointments at three week intervals. Though some patients report seeing improvement earlier, final results are typically observed approximately one month after their final treatment. 

While there is no downtime after a Qwo treatment, significant bruising can occur following injections. Though the bruising tends to be less severe following treatments two and three than after the first treatment, we recommend that patients do not to schedule any of their injection visits prior to events or travel where the bruising may be visible if this is a concern. 

 

Is Qwo Right for Me?

If you're interested in reducing the appearance of cellulite-related dimples on the buttocks, Dr. Day will conduct an evaluation to determine if Qwo might be an effective treatment for you. You should not proceed with treatment if you have an allergy to collagenases or any of the other ingredients in Qwo. If you are unsure about any potential allergies, please discuss any such concerns with Dr. Day.

Estrogen Study

This study is being done to see whether applying a cream with estradiol (a form of estrogen) to the face can improve overall skin quality and help reduce fine lines and wrinkles in peri- and post-menopausal women, and how this relates to epigenetic changes in the skin. A part of the study will also include applying an extra rapamycin analog cream to the face, which is also believed to improve overall skin quality and help reduce fine lines and wrinkles.

WHY THIS MATTERS

Skin aging in peri- and post-menopausal women is deeply tied to hormonal shifts. This study explores whether topical estradiol can turn back the clock – cellularly.

Eligibility

You MAY qualify if you can answer YES to all:

I am a healthy female (peri or menopausal) between the ages of 40 and 65.

I have not had any cosmetic facial treatments in the last 1-3 months.

I have not had any GLP-1 treatments in the last 6 months.

Study Design and Duration

The study includes daily evening application of study cream for 12 weeks, followed by 4 weeks with no test product use. In total, the study will last 16 weeks or approximately 4 months.

Apply to the Estrogen Study

Topical Scalp Serum Containing RLX‑201 in Subjects With Mild‑to‑Moderate Hair Thinning 

Purpose of the Study 

The purpose of this study is to evaluate the safety, tolerability, and effectiveness of a scalp serum containing RLX‑201 when applied once daily for 20 weeks in men and women with mild‑to‑moderate hair thinning. The study will assess changes in hair density, hair thickness, and overall scalp health using clinical evaluations, imaging tools, and participant self‑assessments. 

Eligibility

You MAY qualify if you can answer YES to all:

I am a healthy male or female between the ages of 30 and 60.

Self‑perceived mild‑to‑moderate hair thinning.

I have NOT used minoxidil, light therapy, or other hair growth treatments within 3 months.

I have NOT used medications affecting hair growth (e.g., finasteride, spironolactone, cyproterone acetate, 5‑alpha‑reductase inhibitors) or a GLP-1 within 6 months.

Study Design and Duration 

This is a single‑center clinical study lasting approximately 20 weeks. If you agree to participate, you will be asked to attend study visits at the following time points: Baseline, and Weeks 2, 4, 8, 12, 16, and 20. 

Apply Here